cefadroxil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, cefalosporanic acid derivatives	526	50370-12-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: cefadroxil cefadrox cephadroxil cefadroxil hemihydrate	Long-acting, broad-spectrum, water-soluble, CEPHALEXIN derivative. Molecular weight: 363.39 Formula: C16H17N3O5S CLOGP: -2.51 LIPINSKI: 0 HAC: 8 HDO: 4 TPSA: 132.96 ALOGS: -2.96 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

cefadroxil
cefadrox
cephadroxil
cefadroxil hemihydrate

Long-acting, broad-spectrum, water-soluble, CEPHALEXIN derivative.

Molecular weight: 363.39
Formula: C16H17N3O5S
CLOGP: -2.51
LIPINSKI: 0
HAC: 8
HDO: 4
TPSA: 132.96
ALOGS: -2.96
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
2	g	O

ADMET properties:

Show entries

Search:

Property	Value	Reference
BA (Bioavailability)	95 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
EoM (Fraction excreted unchanged in urine)	93 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	78.62 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System)	4	Bocci G, Oprea TI, Benet LZ
CL (Clearance)	2.50 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.10 hours	Lombardo F, Berellini G, Obach RS
S (Water solubility)	1 mg/mL	Bocci G, Oprea TI, Benet LZ
fu (Fraction unbound in plasma)	0.39 %	Lombardo F, Berellini G, Obach RS
Vd (Volume of distribution)	0.23 L/kg	Lombardo F, Berellini G, Obach RS

Showing 1 to 9 of 9 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Feb. 17, 1978	FDA

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cross sensitivity reaction	384.50	26.84	69	2803	2093	63484057
Type IV hypersensitivity reaction	247.76	26.84	50	2822	2848	63483302
Drug hypersensitivity	107.62	26.84	98	2774	310589	63175561
Nasal oedema	105.02	26.84	22	2850	1500	63484650
Rash maculo-papular	104.71	26.84	43	2829	31853	63454297
Oedema	73.69	26.84	49	2823	97573	63388577
Urticaria thermal	58.53	26.84	11	2861	428	63485722
Asthma	53.47	26.84	45	2827	127516	63358634
Respiratory tract infection	52.40	26.84	29	2843	41454	63444696
Administration site erythema	46.72	26.84	10	2862	755	63485395

Showing 1 to 10 of 21 entries

Previous1 2 3Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cross sensitivity reaction	180.54	26.35	30	658	1367	34954876

Showing 1 to 1 of 1 entries

Previous1Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cross sensitivity reaction	545.05	24.20	99	3135	3613	79737541
Type IV hypersensitivity reaction	259.16	24.20	54	3180	4027	79737127
Nasal oedema	98.94	24.20	21	3213	1703	79739451
Drug hypersensitivity	93.50	24.20	85	3149	298831	79442323
Rash maculo-papular	88.90	24.20	44	3190	56034	79685120
Oedema	78.96	24.20	53	3181	119527	79621627
Asthma	68.58	24.20	51	3183	135044	79606110
Urticaria thermal	59.58	24.20	11	3223	434	79740720
Administration site erythema	55.02	24.20	10	3224	361	79740793
Respiratory tract infection	45.69	24.20	27	3207	48662	79692492

Showing 1 to 10 of 25 entries

Previous1 2 3Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	J01DB05	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS First-generation cephalosporins
CHEBI has role	CHEBI:36047	antibacterial drugs
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents

Showing 1 to 4 of 4 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Infection of skin AND/OR subcutaneous tissue	indication	19824006
Streptococcal tonsillitis	indication	41582007
Klebsiella cystitis	indication	60867007
Urinary tract infectious disease	indication	68566005
Tonsillitis	indication	90176007	DOID:10456
Escherichia coli urinary tract infection	indication	301011002
Proteus urinary tract infection	indication	301012009
Streptococcus pyogenes infection	indication	302809008
Infection due to Staphylococcus aureus	indication	406602003
Prevention of Bacterial Endocarditis	off-label use

Showing 1 to 10 of 12 entries

Previous1 2Next

🐶 Veterinary Drug Use

Show entries

Search:

Species	Use	Relation
Cats	Skin and soft tissue infections caused by susceptible strains of Staphylococcus aureus	Indication
Cats	Genitourinary tract infections caused by Escherichia coli	Indication
Cats	Genitourinary tract infections caused by Proteus species	Indication
Cats	Genitourinary tract infections caused by Staphylococcus aureus	Indication
Cats	Skin and soft tissue infections caused by Pasteurella multocida	Indication
Cats	Skin and soft tissue infections caused by Staphylococcus epidermidis	Indication
Cats	Skin and soft tissue infections caused by Streptococcus species	Indication
Dogs	Skin and soft tissue infections caused by Staphylococcus aureus	Indication
Dogs	Genitourinary tract infections caused by Escherichia coli	Indication
Dogs	Genitourinary tract infections caused by Proteus species	Indication

Showing 1 to 10 of 11 entries

Previous1 2Next

🐶 Veterinary products

Product	Applicant	Ingredients
Cefa-Drops	HQ Specialty Pharma Corp.	1
Cefa-Tabs	HQ Specialty Pharma Corp.	1

Acid dissociation constants calculated using MoKa v3.0.0

Show entries

Search:

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.77	acidic
pKa2	9.72	acidic
pKa3	13.53	acidic
pKa4	7.63	Basic

Showing 1 to 4 of 4 entries

Previous1Next

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Solute carrier family 15 member 1	Transporter	P46059	S15A1_HUMAN		Ki	2.14		WOMBAT-PK
Bacterial penicillin-binding protein	Enzyme		PBPA_ECOLI PBPB_ECOLI DACC_ECOLI PBP2_ECOLI FTSI_ECOLI DACA_ECOLI DACB_ECOLI	INHIBITOR				CHEMBL	CHEMBL

Showing 1 to 2 of 2 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
004959	NDDF
119922-85-9	SECONDARY_CAS_RN
1297878	RXNORM
13414000	SNOMEDCT_US
280111G160	UNII
372651006	SNOMEDCT_US
4018151	VUID
4018151	VANDF
47965	PUBCHEM_CID
4831	IUPHAR_LIGAND_ID

Showing 1 to 10 of 19 entries

Previous1 2Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3196	CAPSULE	500 mg	ORAL	ANDA	22 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3196	CAPSULE	500 mg	ORAL	ANDA	22 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	0093-4059	TABLET	1000 mg	ORAL	ANDA	23 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9766	POWDER, FOR SUSPENSION	500 mg	ORAL	ANDA	21 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9767	POWDER, FOR SUSPENSION	250 mg	ORAL	ANDA	21 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9947	CAPSULE	500 mg	ORAL	ANDA	21 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9948	TABLET, FILM COATED	1 g	ORAL	ANDA	23 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	10544-135	CAPSULE	500 mg	ORAL	ANDA	19 sections
CEFADROXIL	Human Prescription Drug Label	1	16590-043	CAPSULE	500 mg	ORAL	ANDA	23 sections
Cefadroxil	Human Prescription Drug Label	1	16714-388	CAPSULE	500 mg	ORAL	ANDA	21 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next